Endometriosis affects around 1 in 10 women of reproductive age in the UK, yet the average time to diagnosis is more than 9 years. NICE's draft early use healthtech guidance recommends Endosure and ...

People with polyendocrine metabolic ovarian syndrome (PMOS) should have their condition diagnosed sooner and be offered an annual review to monitor symptoms, treatment and long-term health risks, ...

A new treatment option is now available on the NHS for cervical cancer that has come back or spread to other parts of the body, following our final draft guidance published today.

Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer TA1167 18 June 2026 18 June 2026 ...

Browse guidance by topic Cancer Biliary tract cancers Bladder cancer Blood and bone marrow cancers Brain cancers Breast cancer Cervical cancer Colorectal cancer Complications of cancer Endometrial ...

There is a simple discount patient access scheme for pirtobrutinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There is a simple discount patient access scheme for mirvetuximab soravtansine. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There is a commercial access agreement for daratumumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact jnj_imukcs@its.jnj.com ...

This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well ...

This guidance has been updated and replaced by obesity: identification, assessment and management ...

Decisions about updating our guidance are made by NICE’s prioritisation board. For more information on the principles and process, see NICE-wide topic prioritisation: the manual. For information about ...